Results 181 to 190 of about 115,762 (301)

CD30 Expression in Neoplastic Mast Cells and the Presence of CD30+, CD3+, and PAX‐5+ Tumour‐Infiltrating Lymphocytes as Prognostic Markers in Canine Cutaneous Mast Cell Tumours

Veterinary and Comparative Oncology, EarlyView.
ABSTRACT Canine cutaneous mast cell tumour (MCT) is the most common skin neoplasm in dogs, with histopathology serving as both the diagnostic and primary prognostic tool. However, identifying reliable biomarkers is essential for improving clinical decision‐making.
Fernanda Ramalho Ramos, Janayna Maria Parente Serafim, Bethânia Almeida Gouveia, Pedro Luiz Porfirio Xavier, Juliano Rodrigues Sangalli, Heidge Fukumasu, Ricardo de Francisco Strefezzi   +6 more
wiley   +1 more source

Evolutionary regulation of human Fas ligand (CD95L) by plasmin in solid cancer immunotherapy. [PDF]

Nat Commun
Wamba BEN, Mondal T, Freenor V F, Shaheed M, Pang O, Bedinger D, Legembre P, Devel L, Bhatnagar S, Leiserowitz GS, Tushir-Singh J.   +10 more
europepmc   +1 more source

Exercise serum promotes DNA damage repair and remodels gene expression in colon cancer cells

International Journal of Cancer, Volume 158, Issue 10, Page 2641-2649, 15 May 2026.
What's New? Exercise releases bioactive molecules into the bloodstream that can directly slow cancer cell growth. In colon cancer, this may help limit disease progression. Here, using colon cancer cells, the authors investigated the effects of exercise‐conditioned human serum on DNA repair mechanisms. Notably, acute exercise in humans elicited systemic
Samuel T. Orange, Emily Dodd, Sharanya Nath, Hannah Bowden, Alastair R. Jordan, Hannah Tweddle, Ann Hedley, Ifeoma Chukwuma, Ian Hickson, Sweta Sharma Saha   +9 more
wiley   +1 more source

Strong activation of p53 by actinomycin D and nutlin-3a overcomes the resistance of cancer cells to the pro-apoptotic activity of the FAS ligand. [PDF]

Apoptosis
Łasut-Szyszka B, Gdowicz-Kłosok A, Krześniak M, Głowala-Kosińska M, Będzińska A, Rusin M.   +5 more
europepmc   +1 more source

Efficacy and safety of fruquintinib combined with albumin‐bound paclitaxel as second‐line therapy for advanced gastric cancer following failure of PD‐1 inhibitor‐containing treatment (TACTIC GC‐01): A phase II single‐arm study

International Journal of Cancer, Volume 158, Issue 9, Page 2219-2228, 1 May 2026.
What's new? Anti‐angiogenic drugs have shown promising efficacy as a second‐line treatment for advanced gastric cancer. However, it remains unclear how alterations in the tumor microenvironment following first‐line immunotherapy may impact tumor angiogenesis and influence subsequent therapeutic outcomes. This single‐arm study prospectively explored the
Xiaoting Ma, Kai Ou, Xiu Liu, Biyang Cao, Wenwei Yang, Jingyu Lu, Letian Zhang, Qi Wang, Lizhen Gao, Zhichao Jiang, Yongkun Sun, Lin Yang   +11 more
wiley   +1 more source

Matrix metalloproteinase/Fas ligand (MMP/FasL) interaction dynamics in COVID-19: An in silico study and neuroimmune perspective. [PDF]

Heliyon
Saleki K, Aram C, Alijanizadeh P, Khanmirzaei MH, Vaziri Z, Ramzankhah M, Azadmehr A.   +6 more
europepmc   +1 more source

The role of T cells in sepsis of distinct infectious aetiologies

Clinical and Translational Discovery, Volume 6, Issue 2, April 2026.
Pathogen‐specific sepsis induces mitochondrial dysfunction in T cells, leading to functional alterations. Single‐cell transcriptomics reveals subtype‐specific impairments involving reactive oxygen species accumulation, mtDNA damage, calcium dysregulation, and metabolic reprogramming.
Xuanqi Liu, Bijun Zhu, Wanxin Duan, Ruixiang Kang, Xiangdong Wang, Liyang Li   +5 more
wiley   +1 more source

Prognostic Value of Fas/Fas Ligand Expression on Circulating Tumor Cells (CTCs) and Immune Cells in the Peripheral Blood of Patients with Metastatic Breast Cancer. [PDF]

Cancers (Basel)
Papadaki MA, Papadaki E, Chatziavraam S, Aggouraki D, Michaelidou K, Fotsitzoudis C, Vassilakopoulou M, Mavroudis D, Agelaki S.   +8 more
europepmc   +1 more source

Downregulation of Organ‐Derived Activin A Attenuates Muscle Atrophy and Intramuscular Fat Infiltration in Cancer Cachexia Mice

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 2, April 2026.
ABSTRACT Background Cancer cachexia is a multifactorial wasting syndrome marked by profound skeletal muscle loss. Tumours can release high levels of Activin A (ActA), which activates the ubiquitin‐proteasome pathway (UPP) and drives muscle wasting.
Cui Wang, Lin Gao, Rui Xue, Jia Su, Honghui Li, Wei Yang, Yan Tang, Zhihang Su, Shasha Min, Changyong Tang, Yuqi Zhu, Bo Mu, John R. Speakman, Xina Xie, Zesong Li   +14 more
wiley   +1 more source

Results and Exploratory Biomarker Analyses of a Phase II Study CHANGEABLE: Combination of PD‐1 Inhibitor and Niraparib in GErm‐Line‐mutAted Metastatic Breast Cancer

MedComm, Volume 7, Issue 4, April 2026.
This phase II trial evaluated the efficacy and safety of niraparib combined with HX008 in metastatic breast cancer (MBC) patients with germline DNA damage response (DDR) gene mutations. This chemotherapy‐free regimen demonstrates promising efficacy and a tolerable safety profile in MBC patients with germline DDR mutations, providing a novel therapeutic
Jian Zhang, Yiqun Du, Yanchun Meng, Yizi Jin, Mingxi Lin, Xuchen Shao, Xiaojun Liu, Yuxin Mu, Yun Liu, Zhen Hu   +9 more
wiley   +1 more source